Stokes, Margaret G. M., Titball, Richard W., Neeson, Brendan N., Galen, James E., Walker, Nicola J., Stagg, Anthony J., Jenner, Dominic C., Thwaite, Joanne E., Nataro, James P., Baillie, Les ![]() |
Abstract
Bacillus anthracis is the causative agent of anthrax, a disease that affects wildlife, livestock, and humans. Protection against anthrax is primarily afforded by immunity to the B. anthracis protective antigen (PA), particularly PA domains 4 and 1. To further the development of an orally delivered human vaccine for mass vaccination against anthrax, we produced Salmonella enterica serovar Typhimurium expressing full-length PA, PA domains 1 and 4, or PA domain 4 using codon-optimized PA DNA fused to the S. enterica serovar Typhi ClyA and under the control of the ompC promoter. Oral immunization of A/J mice with Salmonella expressing full-length PA protected five of six mice against a challenge with 105 CFU of aerosolized B. anthracis STI spores, whereas Salmonella expressing PA domains 1 and 4 provided only 25% protection (two of eight mice), and Salmonella expressing PA domain 4 or a Salmonella-only control afforded no measurable protection. However, a purified recombinant fusion protein of domains 1 and 4 provided 100% protection, and purified recombinant 4 provided protection in three of eight immunized mice. Thus, we demonstrate for the first time the efficacy of an oral S. enterica-based vaccine against aerosolized B. anthracis spores.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Pharmacy |
ISSN: | 00199567 |
Last Modified: | 17 Oct 2022 08:45 |
URI: | https://orca.cardiff.ac.uk/id/eprint/960 |
Citation Data
Cited 56 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |